CLRB — Cellectar Biosciences Income Statement
0.000.00%
Last trade - 00:00- $14.36m
- $3.32m
- 14
- 20
- 34
- 10
Annual income statement for Cellectar Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 15.1 | 24.1 | 28.8 | 39 | 51.8 |
| Operating Profit | -15.1 | -24.1 | -28.8 | -39 | -51.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -15.1 | -24.1 | -28.7 | -42.8 | -44.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -15.1 | -24.1 | -28.6 | -42.8 | -44.6 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -15.1 | -24.1 | -28.6 | -42.8 | -44.6 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -15.1 | -24.1 | -28.6 | -42.8 | -44.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -231 | -130 | -122 | -105 | -36.5 |